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INTRODUCTION 
The pharmaceutical industry has made considerable 
interest making it a major participant in the healthcare 
industry. The advances and progress made by 
pharmaceutical industry have greatly contributed in terms 
of treatment of disease, thereby enhancing the quality of 
life
1
. Amongst the various routes of drug delivery, the oral 
route is most preferred to the patient and the clinician  
alike. However, peroral administration of drugs has 
Disadvantages such as hepatic first pass metabolism and 
enzymatic degradation within the gastro intestinal (GIT), 
that prohibit oral administration of certain classes of drugs 
especially peptides and proteins. Other absorptive 
mucosae, are considered as potential site for drug 
administration. Transmucosal routes of drug delivery 
(mucosal linings of nasal, rectal, Vaginal, ocular and oral 
cavity) offers distinct advantages over peroral 
administration for Systemic drug delivery. These 
advantages include possible bypass of first pass effect, 
Avoidances of pre-systemic elimination within GIT  and 
better enzymatic flo ra for drug absorption
1-3
. In buccal 
drug delivery, the buccal mucosa is the preferred region as 
compared to the sublingual mucosa. One of the reasons is 
that buccal mucosa is  less permeable and is thus not able to 
elicit a rapid onset of absorption and hence better suited 
for formulations that are intended for sustained release 
action. Further, the buccal mucosa being relatively  
immobile mucosa and readily accessible, it makes  it  more 
advantageous for retentive systems used for oral 
transmucosal drug delivery. Over the past few decades, the 
concept of use of bioadhesive polymers to prolong the 
contact time has gained remarkable attention in 
transmucosal drug delivery. Adhesion as a process is 
simply defined as the “fixing” of two surfaces to one 
another. Bioadhesion may be defined as the state in which 
two materials, at least one of which is biological 
membrane, are held together by means of interfacial 
forces. In the pharmaceutical sciences, when the adhesive 
attachment is to mucus or a mucous membrane, the 
phenomenon is referred to as mucoadhesion
4
. Drug 
absorption into the oral mucosa is main ly via passive 
diffusion into the lipoidal membrane. Compounds with 
partition coefficient in the range 40-2000 and pKa 2-10 are 
considered optimal to be absorbed through buccal mucosa. 
Compounds admin istered by buccal route include steroids, 
barbiturates, papain, trypsin etc
5
. 
 In 1980’s, Professor Joseph R. Robinson at the University 
of Wisconsin pioneered the concept of mucoadhesion as a 
new strategy to prolong the residence time of various drugs 
on the ocular surface.  Mucoadhesive polymers were 
shown to be able to adhere to various other mucosal 
membranes. The capability to adhere to the mucus gel 
layer which covers epithelial tissues makes such polymers 
very useful excip ients in drug delivery
6
. Buccal patches are 
highly flexible and thus much more readily tolerated by the 
patient than tablets. Buccal patches are more accurate 
dosing than gels and ointments
7
. Mucoadhesive drug 
delivery systems are delivery systems which utilize the 
ABSTRACT 
 Over the last few years Pharmaceutical scientists are trying to explore transdermal and transmucosal routes as an 
alternative to injections. Buccal delivery of the desired drug using mucoadhesive polymers has been the subject of 
interest since the early 1980s. Conventional dosage forms for delivery of drugs via the oral mucosa include solutions, 
erodible or chewable, buccal or sublingual tablets and capsules. Unfortunately, a major portion of the drug in these 
systems may be unavailable due to involuntary swallowing and a very short residence time, because of mastication, 
speech etc and hence sustained release is usually not within the scope of such Formulations and development of Novel 
bioadhesive dosage forms for mucosal delivery of drugs that attempt to overcome these limitations. We formulated 
buccal drug delivery, the buccal cavity was found to be the most convenient and easily accessible site for the delivery of 
therapeutic agents for both local and systemic delivery as retentive dosage forms. Because buccal Adhesive drug delivery 
system prolong the residence time of the dosage form at the site of application or absorption and facilitate an intimate 
contact of the dosage form with the limited absorption surface and thus contribute to improved  better therapeutic 
efficacy of the drug. Buccal administration of drugs  provides a convenient route of administration for both systemic and 
local drug actions. Buccal drug delivery has gained significant attention and momentum since it offers remarkable 
advantages. This review article is an overview of buccal drug delivery systems encompassing a review of oral mucosa, 
active ingredient delivered via buccal route by different mucoadhesive formulations. Including, commercial technologies  
and future prospects of this route of drug delivery are discussed.  
Keywords: Mucoadhesion, Mucoadhesive polymers, Microspheres, Controlled drug delivery  
 
Mamatha et al                                 Journal of Drug Delivery & Therapeutics; 2012, 2(2)   27 
© 2011, JDDT. All Rights Reserved                                                                                                                                                      ISSN: 2250-1177 
property of bioadhesion of certain polymers, which  
become adhesive on hydration. The attachment as 
adhesion could be between a polymer and a biological 
membrane. In the case of polymer attached to the mucin  
layer of a mucosal tissue, the term mucoadhesion is used. 
The mucosal layer lines a number of regions of the body 
including gastrointestinal tract, urogenital tract, ear, nose 
and eye. These represent potential sites for attachment of 
any bioadhesive system and hence, the mucoadhesive drug 
delivery system includes: Buccal drug delivery, Oral drug 
delivery, vaginal drug delivery, rectal drug delivery, nasal 
drug delivery and ocular drug delivery
8
.  
BUCCOADHES IVE DRUG DELIVERY S YS TEM  
The buccal region offers an attractive route of 
administration for systemic drug delivery. The mucosa has 
a rich blood supply and it is relatively permeable. The oral 
mucosa can be distinguished according to five major 
regions in the oral cavity.  
 The buccal mucosa (cheeks) 
 The gum (gingival) 
 The palatal mucosa 
 The inner side of the lips  
 The floor of the mouth (sublingual region)  
In oral cavity, delivery of drugs can be classified into three 
categories
10
:  
 Buccal delivery  
 Sublingual delivery  
 Local delivery 
IDEAL CHARACTERISTICS OF BUCCAL DRUG 
DELIVERY
11
 
 Should have good wetting and solubility and 
biodegradability properties  
 Polymer and its degradation products should not be 
non-toxic, and free from leachable impurities  
 Should adhere quickly to buccal mucosa and should 
posses sufficient Mechanical strength, Should posses 
peel, tensile and shear strength at the bio adhesive 
range 
 Polymer should be easily available and its cost should 
not be high 
 Should show bioadhesive properties in both dry and 
liquid state  
 Should demonstrate local enzyme inhib ition and 
penetration enhancement properties, should posses 
adhesively active groups 
 Should have optimum molecular weight  
 Should demonstrate acceptable shelf life                                                                     
 Should have required spatial confirmation 
 Should be sufficiently cross-linked but not to the 
degree of suppression of bond forming groups
 
ADVANTAGES  OF BUCCAL DRUG DELIVERY  
 Bypass of the gastrointestinal tract and hepatic portal 
system, increasing the bioavailability of orally  
administered drugs that otherwise undergo hepatic first-
pass metabolism, Improved patient compliance due to the 
elimination of associated pain with injections, Sustained 
drug delivery and a relatively rapid onset of action can be 
achieved relative to the oral route and the formulation can 
be removed if therapy is required to be discontinued. 
Increased ease of drug administration, The large contact 
surface of the oral cav ity contributes to rapid and extensive 
drug absorption, Extent of perfusion is more therefore 
quick and effective absorption, nausea and vomiting are 
greatly avoided. Used in case of unconscious and less 
cooperative patients. Drugs, which show poor 
bioavailability via the oral route, can be administered 
conveniently, ex; drugs which are unstable in the acidic 
environment of the stomach or are destroyed by the 
enzymatic or alkaline environment of the intestine
12, 13,14
. 
DISVANTAGES  OF MUCOADHES IVE BUCCAL 
DRUG DELIVERY 
Once placed at the absorption site & the dosage form 
should not be disturbed. The drug swallowed in saliva is 
lost. Properties like unpleasant taste or odour, irritability to 
the mucosa & stability at salivary pH possess limitations to 
the choice of drug. Only drugs with small dose can be 
administered, eating and drinking may become restricted
15, 
16
.  
MECHANIS M OF BIOADHES ION 
Bioadhesion is an interfacial phenomenon in which two  
materials, at least one of which is biological, are held  
together by means of interfacial forces. The attachment 
could be between an artificial material and biological 
substrate, such as adhesion between polymer and/or 
copolymer and a biological membrane. In case of polymer 
attached to the mucin layer of the mucosal tissue, the term 
“mucoadhesion” is employed. “Bioadhesive” is defined as 
a substance that is capable of interacting with biological 
material and being retained on them or holding them 
together for extended period of t ime.  
In the study of adhesion generally, two steps in 
the adhesive process have been identified, which have 
been adapted to describe the interaction between 
mucoadhesive materials and a mucous membrane as 
shown below (Fig 1): 
 
Figure 1:  Stages in mucoadhesion (Adopted from N.S. 
Miller et al; Adv Drug Del Rev; 2005)
13
 
Type 1. Contact Stage  
An intimate wetting occurs between the mucoadhesive and 
mucous membrane. In some cases these two surfaces can 
be mechanically brought together, e.g. placing and holding 
a delivery system within the oral cavity, eye or vagina.  
Type 2. Consolidation Stage  
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Figure 2: The three regions within a mucoadhesive 
joint (Adopted from J.D. Smart et al., Adv Drug Del 
Rev; 2005)
4
 
Different physicochemical interactions happen to combine 
and toughen the adhesive joint, leading to long-lasting 
adhesion (Fig 2). Mucoadhesive materials adhere most 
strongly to solid dry surfaces as long as they are activated 
by the presence of moisture and will effectively  plasticize 
the system allowing mucoadhesive molecules to become 
free, conform to the shape of the surface and bond 
predominantly by hydrogen and weaker van der Waal 
bonding. 
 
Type 3. The Removal Mechanism
 
Adhesive failure will normally occur at the weakest 
component of the joint. For weaker adhesives this would 
be the mucoadhesive-mucus interface, for stronger 
adhesives this would initially be the mucus layer, but later 
may be the hydrating mucoadhesive material. The possible 
regions for mucoadhesive joint failure are shown in Fig 3. 
  
Figure 3: The possible regions for 
mucoadhesive joint failure 
(Adopted from JD Smart et al, Adv Drug Del Rev; 
2005)
4
 
THEORIES OF BIOADHES ION  
Several theories have been proposed to explain the 
fundamental mechanis m of adhesion.  
Wetting theory: Wetting theory is predominantly 
applicable to liquid bioadhesive systems and analyzes 
adhesive and contact behavior in terms of a liquid or a 
paste to spread over a biological system. The work of 
adhesion (expressed in terms of surface and interfacial 
tension (γ) being defined as energy per cm2 released when 
an interface is formed). According to Dupres equation.  
Diffusion theory: According to this theory, the polymer 
chains and the mucus mix to a sufficient depth to create a 
semi-permanent adhesive bond. The exact depth to which 
the polymer chains penetrate the mucus depends on the 
diffusion coefficient and the time of contact. This diffusion 
coefficient, in turn, depends on the value of molecu lar 
weight between cross links and decreases significantly as 
the cross linking density decreases. 
Electronic theory: According to this theory, electronic 
transfer occurs upon contact of an adhesive polymer and 
the mucus glycoprotein network because of differences in 
their electronic structure. This result in  the formulation of 
an electronic double layer at the interface adhesion occurs 
due to attractive forces across the double layer. 
Fracture theory: Fracture theory of adhesion is related to 
separation of two surfaces after adhesion. The fracture 
strength is equivalent to adhesive strength.  
Adsorption theory: According to this theory, after an 
initial contact between two surfaces, the materials adhere 
because of surface forces acting between the atoms in the 
two surfaces. Two types of chemical bonds such as 
primary covalent (permanent) and secondary chemical 
bonds (including electrostatic forces, vander Waals forces 
and hydrogen and hydrophobic bonds) are involved in the 
adsorption process
18
. 
FACTORS AFFECTING BIOADHES ION
 
Structural and physicochemical properties of a potential 
bioadhesion material influence bioadhesion. 
Polymer related factors  
Molecular weight: The bioadhesive force increases with 
molecular weight of polymer up to 10,000 and beyond this 
level there is no much effect. To allow chain  
interpenetration, the polymer molecule must have an 
adequate length.  
Concentration of active polymers: There is an optimum 
concentration of polymer corresponding to the best 
bioadhesion. In highly concentrated systems, the adhesive 
strength drops significantly. In concentrated solutions, the 
coiled molecules become solvent poor and the chains 
available for interpenetration are not numerous. 
Flexibility of polymer chain: Flexib ility is an important 
factor for interpenetration and enlargement. As water 
soluble polymers become cross linked, the mobility of 
individual polymer chain decreases. As the cross linking  
density increases, the effective length of the chain which 
can penetrate into the mucus layer decreases further and 
mucoadhesive strength is reduced.  
Environment related factors 
pH: The pH influences the charge on the surface of both 
mucus and the polymers. Mucus will have a different 
charge density depending on pH Because of difference in  
dissociation of functional groups on the Carbohydrate 
moiety and amino acids of the polypeptide back bone.  
Strength: To place a solid bioadhesive system, it is 
necessary to apply a defined strength.  
Initial contact time: The mucoadhesive strength increases 
as the initial contact time increases.  
Selection of the model substrate surface: The v iability of 
biological substrate should be confirmed by examin ing 
properties such as permeability, Electrophysiology of 
histology.  
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Swelling: Swelling depends on both polymers 
concentration and on presence of water. When swelling is 
too great a decrease in bioadhesion occurs.  
Physiological variables 
Mucin turnover: The natural turnover from the mucus 
layer is important for at least two reasons.  
 The mucin turnover is expected to limit the residence 
time of the mucoadhesive on the mucus layers.  
 Mucin turnover results in substantial amounts of 
soluble mucin molecu les.  
Diseased states: Physicochemical properties of mucus are 
known to Change during diseased states, such as common 
cold, gastric ulcers, Ulcerative colitis, cystic fibrosis, 
bacterial and fungal infect ions of the Female reproductive 
tract and inflammatory conditions of the eye
19,20
.  
FORMULATIONS FOR BUCCAL DRUG 
DELIVERY  
Buccal adhesive drug delivery systems with the size 1–3 
cm
2
 and a daily dose of 25 mg or less are preferab le. The 
maximal duration of buccal delivery is approximately 4–6 
h.   
Buccal adhesive polymers  
Mucoadhesive polymers are the important component in 
the development of buccal delivery systems. These 
polymers enable retention of dosage form at the buccal 
mucosal surface and thereby provide intimate contact 
between the dosage form and the absorbing tissue. These 
formulat ions are often water soluble and when in a dry 
form attract water from the bio logical surface which in  
turn leads to a strong interaction between the dosage form 
and mucosal layer.  
An ideal polymer for a mucoadhesive drug delivery system 
should have the following characteristics.  
 The polymer and its degradation products should be 
nontoxic and nonabsorbable in the gastrointestinal 
tract  
 It should be nonirritant to the mucus membrane  
 It should preferably form a strong noncovalent bond 
with the mucin ep ithelial cell surfaces  
 It should adhere quickly to moist tissue and should 
possess some site specificity 
 It should allow easy incorporation of the drug and 
offer non hindrance to its release.  
 The polymer must not decompose on storage or during 
shelf-life o f the dosage form 
Criteria followed in polymer selection  
 It should form a strong non covalent bond with the 
mucin/epithelial surface  
 It must have high molecular weight and narrow 
distribution 
It should be compatible with the biological membrane
21
. 
The polymers that are commonly used as Bioadhesive in 
pharmaceutical applicat ions are in Table. 01 
Table: 1 Mucoadhesive polymers used in the oral cavity
43 
Criteria Categories Examples  
 
 
 
Source 
 
Semi natural  
 
Agarose, chitosan, gelatin, Hyaluronic acid, Various 
gums (guar, xanthan, gellan, carragenan, pectin and 
sodium alg inate) 
Cellulose derivatives 
[CMC, thiolated CMC, Sodium 
CMC, HEC, HPC, HPMC, 
MC, MHEC] 
Thiloated CMC,HEC,HPC,  
Poly(acrylic acid)-based polymers [CP, PC, PAA, 
polyacrylates, poly(methylvinylether-co-methacrylic 
acid), PVA  
 
 
Aqueous solubility 
Water-soluble CP, HEC, HPC (waterb38 8C), HPMC (co ld water), 
PAA, sodium CMC, sodium alginate 
Water-insoluble Chitosan (soluble in dilute aqueous acids), EC, PC 
 
 
Charge 
Cationic  Aminodextran, chitosan, (DEAE)-dextran, TMC 
Anionic Chitosan-EDTA, CP, CMC, pectin, PAA, PC, sodium 
alginate,sodium CMC, xanthan gum 
Non-ionic  Hydroxyethyl starch, HPC, poly(ethylene oxide), 
PVA, PVP, scleroglucan 
 
GENERAL CONS IDERATIONS IN FORMULATION 
DES IGN 
Physiological considerations  
The designing of buccal dosage form physiological factors 
such as surface of buccal mucosa, limit ing device size, 
drug load, thickness of the mucus layer, its turn over time, 
effect of saliva and other environmental factors  are to be 
considered. Saliva contains certain enzymes (esterases, 
carbohydrases, phosphatases) that may degrade some 
drugs. Although saliva secretion facilitates the dissolution 
of drug, involuntary swallowing of saliva also affects its 
bioavailability. Saliva has a weak buffering capacity to 
maintain pH value within local regions. These 
disadvantages can be avoided by developing unidirectional 
release systems with backing layer. Th is concept may also 
results in high drug bioavailability
22. 
Pharmacological considerations 
Buccal d rug absorption depends on the partition coefficient 
of the drugs. Lipophilic drugs absorb through the 
transcellular route, where as hydrophilic d rugs absorb 
through the paracellular route. This behaviour leads to the 
assumption that chemical modification may increase drug 
penetration through buccal mucosa. Increasing nonionized 
fraction of ionisable drugs increases drug penetration 
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through trans-cellular route. In weakly basic drugs, the 
decrease in pH increases the ionic fract ion of drug but 
decreases its permeability through buccal mucosa. Other 
pharmacological factors include residence time and local 
concentration of the drug in the mucosa, treatment of oral 
diseases, the amount of drug transported across the mucosa 
into the blood. Similar dependencies on partition 
coefficients were obtained from acyclovir, β- 
adrenoreceptor blocking agents and substituted 
acetanilide
21
. 
Pharmaceutical considerations  
Factors affecting the drug release, penetration through 
buccal mucosa, organoleptic factors, and effects of other 
excip ients used to improve drug release pattern and 
absorption, irritation caused at the site of application are to 
be considered while designing a formulation. Excipients 
enhancing palatial properties are often required to improve 
acceptability of dosage form or masking less/desirable 
properties of the bioactive constituent. Some addit ives can 
be incorporated to improve drug release pattern and 
absorption. Ideally pharmaceutical buccal adhesive drug 
delivery systems should contain mucoadhes ive agents, 
penetration enhancers and enzyme inhib itors. 
Mucoadhesive agents are used to maintain an intimate and 
prolonged contact of the formulation with the absorption 
site while penetration enhancers improve the drug 
permeat ion across mucosa (trans-mucosal delivery) or into 
deepest layers of the epithelium (mucosal delivery). The 
enzyme inhibitors ideally protect the drug from the 
degradation by means of mucosal enzymes
21. 
BUCCAL MUCOADHES IVE DOSAGE FORMS  
Buccal dosage forms are meant to be placed between 
gingival and cheek. Buccal adhesive dosage forms are 
those dosage forms which can deliver drugs either locally 
to treat conditions within the buccal cavity or systemically  
via the mucosa. It often requires that buccal-adhesive 
dosage forms should remain adhesive and allow a 
controlled delivery of drug for prolonged periods. 
Therefore, for sustained drug delivery, buccal adhesive 
formulat ions must contain elements that remain adhesive 
for a prolonged period, regulate the rate and direction of 
drug delivery
9, 21, 22
. The different types of Buccoadhesive 
dosage forms are  
Buccal tablets 
Buccal tablets are intended to be held in the mouth, where 
they release their drug contents for absorption directly 
through the oral mucosa. A buccal tablet may release drug 
rapidly or may be designed to release drug slowly for a 
prolonged effect, give improved bioavailability of drug 
due to avoidance of first-pass metabolism and also 
improves patient compliance by reducing repetitive dose. 
Unlike conventional buccal tablets, these tablets can be 
applied to different sites in the oral cavity, including the 
palate, the mucosa lining the cheek, as well as between the 
lip and the gum. Successive tablets can be applied to 
alternate sides of the mouth. Bioadhesive tablets are 
usually prepared by direct compression, but wet 
granulation techniques can also be used. Tablets intended 
for buccal administration by insertion into the buccal 
pouch may dissolve or erode slowly; therefore, they are 
formulated and compressed with sufficient pressure only to 
give a hard tablet
23
. 
Buccal films 
Films are the most recently developed dosage form for 
buccal administration. Buccal films may be preferred over 
adhesive tablets in terms of flexibility and comfort. 
Bioadhesive films are similar to laminated patches in terms 
of their flexib ility and manufacturing process. They are 
usually manufactured by a solvent casting method. The 
drug and polymer(s) are first dissolved in a casting solvent 
or solvent mixture. The solution is then cast into films, 
dried and finally laminated with a backing layer o r a 
release liner. The backing layer helps to retard the 
diffusion of saliva into the drug layer, thus enhancing the 
adhesion time and reducing drug loss into the oral cavity. 
The solvent casting method is simple, but suffers from 
some disadvantages, including long processing time, h igh 
cost and environmental concerns due to the solvents used. 
These drawbacks can be overcome by the hot-melt  
extrusion method
24, 25
. 
Buccal gels and ointments 
Semisolid dosage forms, such as gels and ointments have 
the advantage of easy dispersion throughout the oral 
mucosa. Drug dosing from semisolid dosage forms may  
not be as accurate as from tablets, patches or films. Poor 
retention of the gels at the site of application has been 
overcome by using bioadhesive formulations. Certain  
bioadhesive polymers, e.g. HPMC, poloxamer 407, sodium 
carboxymethylcellu lose, Carbopol, hyaluronic acid and 
xanthan gum undergo a phase change from a liquid to a 
semisolid. Th is change enhances the viscosity, which 
results in sustained and controlled release of drugs. A 
highly viscous gel was developed from Carbopol and 
hydroxyl propyl cellu lose for ointment dosage forms that 
could be maintained on the tissue for up to 8 h
9, 22
. 
Buccal patches 
Patches are laminates consisting of an impermeable 
backing layer, the drug containing reservoir layer from 
which the drug is released in a controlled manner and a 
bioadhesive surface for mucosal attachment. Buccal patch 
systems are similar to those used in transdermal drug 
delivery. Two methods used to prepare adhesive patches 
include solvent casting and direct milling. In  the solvent 
casting method, the intermediate sheet from which patches 
are punched is prepared by casting the solution of the drug 
and polymer(s) onto a backing layer sheet and 
subsequently allowing the solvent(s) to evaporate. In the 
direct milling method, formulation constituents are 
homogeneously mixed and compressed to the desired 
thickness and patches of predetermined size and shape are 
then cut or punched out
24, 25
. 
FORMULATION DES IGN  
In the case of both mucosal and transmucosal 
administration, conventional dosage forms are not able to 
assure therapeutic drug levels on the mucosa and in the 
circulat ion. This is because of the physiological removal 
mechanis ms of the oral cavity (washing effect of saliva 
and mechanical stress), to obtain the therapeutic action, it 
is therefore necessary to prolong and improve the contact 
between the active substance and the mucosa. To fu lfill the 
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therapeutic requirements, formulations designed for buccal 
administration should contain the following functional 
agents: mucoadhesive agents, to maintain an intimate and 
prolonged contact of the formulation with the absorption 
site; penetration enhancers, to improve drug permeat ion 
across mucosa (transmucosal delivery) or into deepest 
layers of the epithelium and enzyme inhib itors, to 
eventually protect the drug from the degradation by means 
of mucosal enzymes
26, 19, 21
. 
Mucoadhesive agents 
Different situations for buccal mucoadhesion are possible 
depending on the dosage form. In the case of dry or 
partially hydrated formulat ions, polymer hydration and 
swelling properties probably play the main role. The 
polymer hydration and consequently the mucus 
dehydration could cause an increase in mucous cohesive 
properties that promote mucoadhesion. Swelling should 
favour polymer chain  flexibility and interpenetration 
between polymer and mucin chains. So, depending on the 
type of formulat ion, polymers with d ifferent characteristics 
have to be considered, 
 The polymers that adhere to the mucin-epithelial surface 
can be conveniently divided into three broad categories:  
 Polymers that become sticky when p laced in water 
and owe their bio adhesion to Stickiness  
 Polymers that adhere through nonspecific, 
noncovalent interactions that are primarily  
electrostatic in nature  
 Polymers that bind to specific receptor sites on the cell 
surface
22
. 
Permeation enhancers  
Penetration enhancers are also required when a drug has to 
reach the systemic circulat ion to exert its action. These 
must be non-irritant and have a reversible effect the 
epithelium should recover its barrier properties after the 
drug has been absorbed. The most common classes of 
buccal penetration enhancers include fatty acids (that act 
by disrupting intercellular lipid packing), surfactants and 
among these bile salts (by extracting membrane protein or 
lip ids, by membrane fluidizat ion, by producing reverse 
micellization in the membrane and creating aqueous 
channels), azone (by creating a region of fluidity in  
intercellular lipids) and alcohols (by reorganizing the lipid  
domains and by changing protein conformat ion).  
Categories and examples of membrane permeation 
enhancers  
 Bile salts and other steroidal detergents  
 Surfactants: Non-ionic, Cationic, Anionic  
 Fatty acids  
 Other enhancers: Azones, Salicy lates, Chelat ing 
agents, Sulfoxides
27
. 
Mechanism of buccal absorption enhancer  
The mechanism by which enhancers act are been poorly 
understood. Surfactants such as sodium lauryl sulphate 
interact at either the polar head groups or the hydrophilic 
tail regions of the molecules comprising the lipid bilayer 
disrupting the packing of the lipid molecules, increasing 
the fluid ity of the bilayer and facilitating drug diffusion. 
Interaction of enhancers with the polar head groups may 
also cause or permit the hydrophilic regions of adjacent 
bilayer to take up more water and more apart, thus opening 
the par cellular pathway. Non ionic surfactants and long 
chain acids and alcohols also increase membrane 
components, thereby increasing the permeability.  
Agents such as dimethyl sulfoxide, polyethylene glycol 
and ethanol, if p resent in sufficient h igh concentrations in 
the delivery vehicle can enter the aqueous phase of the 
stratum corneum and alter its solubilising properties, 
thereby enhancing the partitioning of drugs from the 
vehicle into the skin.  
Mechanisms by which permeation enhancers are thought 
to improve mucosal absorption include the following. 
 Changing mucus rheology  
 Increasing fluid ity of lip id bilayer membrane  
 Affecting the components involved in the formation of 
intracellular junctions  
 Overcoming the enzymat ic barrier  
 Increasing the thermodynamic activity of drugs 23, 28, 29. 
METHOD OF PREPARATION OF 
MUCOADHES IVE PATCHES  
Mucoadhesive buccal patches can be prepared by methods 
mentioned below;  
Solvent casting method: Mucoadhesive patches are 
prepared by solvent casting method. All ingred ients were 
accurately weighed and mixed in pestle and mortar. Then 
the mixture added gradually to magnetically stir solvent 
system, which contain the plasticizer. Continue the stirring 
until a clear solution is obtained. The solution is then 
transferred quantitatively to Petri-dish. The Petri-dish 
covered with inverted funnels to allow evaporation of the 
solvents. These are kept at 20 - 25 ºC temperature for 24 to 
48 hours depending upon the solvent system used. Size of 
patches are 15 to 20 mm diameter, 0.2 to 0.3 mm thick are 
carefully pull out from the Petri dishes 
30, 31, 32
. 
Semisolid casting: In semisolid casting method, initially  
prepare a solution of water soluble film forming polymer. 
The resulting solution is added to a solution of acid 
insoluble polymer (e.g. cellu lose acetate phthalate, 
cellu lose acetate butyrate), which is  prepared in 
ammonium or sodium hydroxide. Then appropriate amount 
of plasticizer is added so that a gel mass is obtain. Finally  
the gel mass is cast into the films using heat control drums.  
Hot melt extrusion: In hot melt extrusion method, firstly 
the drug is mixed with carriers in solid form. Then the 
extruder containing heaters are used to melt the mixture. In  
the end, the melt are given the shape of films with the help 
of dies. Hot melt ext rusion have merit as patches prepared 
through this method have better content uniformity 
33
. 
Solid dispersion extrusion: In this method immiscible 
components are extruded with drug and then solid 
dispersions are prepared. Finally the solid dispersions are 
shaped into films by mean of dies. 
Rolling method: In rolling method a solution or 
suspension containing drug is rolled on a carrier. So lvent is 
mainly water and mixture of water and alcohol. Film is 
dried on the rollers and cut into desired shapes and sizes
34
. 
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EVALUATION OF BUCCAL PATCHES   
Physical properties  
Physical appearance and surface texture of patch: This 
parameter was checked simply with visual inspection of 
patches and evaluation of texture by feel or touch.  
Weight uniformity of patches: Three patches of the size 
10 mm diameter were weighed indiv idually using digital 
balance and the average weights were calculated. 
Thickness of patches: Thickness of the patches was 
measured using screw gauge with a least count of 0.01mm 
at different spots of the patches. The thickness was 
measured at three different spots of the patches and 
average was taken
35
.  
Folding endurance of patches: The flexib ility of patches 
can be measured quantitatively in terms of what is known 
as folding endurance. Folding endurance of the patches 
was determined by repeatedly folding a small strip of the 
patches (approximately 2x2 cm) at the same place till it  
broke. The number of t imes patches could be folded at the 
same place without breaking gives the value of fold ing 
endurance
36
.  
Swelling index of patches: The swelling Index of the 
patches determined by immersing pre weighed patch of 
size 2cm2 in 50 ml water. The strip was taken out carefu lly  
at 5 &10 min.   intervals, blotted with filter paper & 
weighed accurately
36
. 
Surface pH of patches: Surface pH was determined by the 
patches were allowed in contact with 1ml of distilled  
water. The surface pH was noted by bringing a combined 
glass electrode or pH paper near the surface of patches and 
allowing equilib rating for 1 min.  
Mechanical properties 
Bursting strength of patches: A test for measuring the 
resistance of a film to bursting and reported in kilo-Pascal 
or pounds per square inch or Kg / cm
2
. The bursting 
strength of all the films were evaluated by using standard 
bursting strength tester. 
In vitro residence time of patches: The in vitro residence 
time was determined using IP disintegration apparatus. 
The disintegration medium was 500 mL of simulated 
saliva (pH 6.8), maintained at 37 ± 2 ºC. The segments of 
rat intestinal mucosa, each of 3 cm length, were glued to 
the surface of a glass slab, which was then vertically  
attached to the apparatus. Three mucoadhesive films of 
each formulation were hydrated on one surface using 
simulated saliva (pH 6.8) and the hydrated surface was 
brought into contact with the mucosal membrane. The 
glass slab was vertically fixed to the apparatus  and allowed  
to move up and down. The film was completely immersed 
in the buffer solution at the lowest point and was out at the 
highest point. The time required for complete erosion or 
detachment of the film from the mucosal surface was 
recorded
37
. 
Drug polymer interaction study of patches: There is 
always a possibility of drug-excip ient interaction in any 
formulat ion due to their intimate contact. The technique 
employed in this study to know drug-excipients 
interactions is IR spectroscopy; IR spectroscopy is one of 
the most powerful analytical techniques which offer the 
possibility of chemical identification. Formulations were 
scanned by using Perkin-Elmer FTIR, by a thin film 
method. 
Drug content  uniformity of patches: The patches were 
tested for drug content uniformity by UV- 
Spectrophotometric method. Patches of 10 mm d iameter 
were cut from three d ifferent places from the casted 
patches. Each patch was placed in 100 ml volumetric flask 
and dissolved in simulated saliva pH 6.8 and 1 mL is taken 
and diluted with water up to 10 mL. The absorbance of the 
solution was measured at suitable wavelength using 
UV/visib le spectrophotometer. The percentage drug 
content was determined
38
. 
In vitro drug release: In vitro release studies were carried  
out by attaching sigma d ialysis Membrane to one end of 
the open cylinder which acted as donor compartment 
prepared buccal patches containing drug was placed inside 
donor compartment which is agitated continuously using 
magnetic stirrer and then temperature was maintained at 37 
± 1 ºC. Receptor compartment consist of 100 mL of pH6.8 
simulated saliva, sample of 2 mL were withdrawn at 
periodic intervals from Receptor compartment & replaced 
with fresh phosphate buffer immediately and the drug 
release was analyzed spectrophotometrically at suitable 
wave length. Release rate was studied for all designed 
formulat ions
39, 40, 41, 42
. 
CONCLUS ION 
The buccal mucosa offers several advantages for 
controlled drug delivery for extended periods of time. The 
mucosa is well supplied with both vascular and lymphatic 
drainage and first-pass metabolis m in the liver and pre-
systemic elimination in the gastrointestinal tract are 
avoided. The area is well suited for a retentive device and 
appears to be acceptable to the patient. With the right 
dosage form design and formulation, the permeability and 
the local environment of the mucosa can be controlled and 
manipulated in order to accommodate drug permeation. 
Buccal drug delivery is a promising area for continued 
research with the aim of systemic delivery of orally  
inefficient drugs as well as a feasible and attractive 
alternative for non-invasive delivery of potent peptide and 
protein drug molecules. However, the need for safe and 
effective buccal absorption enhancers is a crucial 
component for a prospective future in the area of buccal 
drug delivery. 
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